Dynamics of chronic heart failure with a low ejection fraction when dapagliflozin is included in standard therapy
Objective. The aim of the current research is the dapagliflozin influence on the key parameters that shows the severity of heart failure among patients with chronic heart failure with low ejection fraction.Materials and methods. The research involves 30 mail patients average aged 61,6 ± 11,1. The ba...
Saved in:
| Main Authors: | A. A. Tsareva, V. A. Razin, S. S. Kosinov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2024-04-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/1202 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01) -
Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01) -
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF
by: Andrew P. Ambrosy, et al.
Published: (2025-06-01) -
Effect of dapagliflozin in paroxysmal atrial fibrillation combined with heart failure with preserved ejection fraction: a randomized controlled trial
by: Xiaoyu LIAN, et al.
Published: (2025-06-01) -
Outcomes and Left Ventricular Ejection Fraction in Cardiac Magnetic Resonance: Challenging the “Higher Is Better”
by: Rungroj Krittayaphong, et al.
Published: (2025-04-01)